Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Pregnancy
Interventions: Hydromorphone, Hyperbaric bupivacaine, Fentanyl; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis
Interventions: hydrocodone / acetaminophen extended release, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 873 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 68 more

Conditions: Thoracic, Pulmonary Disease
Interventions: Gabapentin, Placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Psychology, Social
Interventions: Naltrexone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Dependence
Interventions: Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Dependence
Interventions: Methadone, buprenorphine (Suboxone); Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cocaine-Related Disorders
Interventions: Naltrexone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1996
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Interventions: Buprenorphine; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: Up to 4 Weeks
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Substance-Related Disorders
Interventions: D-cycloserine, Placebo; Drug
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use Disorder
Interventions: Naltrexone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Alcoholism, Alcohol Dependence
Interventions: naltrexone (Revia), cognitive behavior therapy, motivational enhancement therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2002
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Pain
Interventions: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Opioid Overdose, Opiate Overdose
Interventions: Nalmefene Injection, Naloxone Injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Fusion of Spine, Lumbar Region
Interventions: Acetaminophen IV Soln 10 MG/ML, Acetaminophen, Hydromorphone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opiate Dependence, Depression
Interventions: escitalopram, placebo; Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Opioid-Related Disorders
Interventions: Naltrexone, Intravail; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Opioid Use Disorder, Chronic Back Pain, Anxiety
Interventions: low intensity focused ultrasound (LIFU); Device
Lead sponsor: Washington D.C. Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Rhinoplasty, Non-steroidal Ant Inflammatory Drugs, Opioid Use
Interventions: Norco, NSAID; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Post Operative Pain
Interventions: oxymorphone HCl; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 0 Years to 12 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 8
States / cities: Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 5 more

Conditions: Dental Pain
Interventions: Oxycodone, Buprenorphine, Placebo Film, Placebo Capsule; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Austin, Texas • San Marcos, Texas • Salt Lake City, Utah

Conditions: Opioid-Related Disorders, Substance Withdrawal Syndrome
Interventions: Dynorphin 1 - 13; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1997
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pain
Interventions: Naltrexone, then placebo, Placebo, then Naltrexone; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Pain, Abuse, Drug
Interventions: Oxycodone, Cannabis (THC:CBD = ~ 1:0), Cannabis (THC:CBD = ~ 0:1), Cannabis (THC:CBD = ~ 1:1), Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 53 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Intrathecal Hydromorphone for Labor Analgesia

A Study of Pain Relief in Osteoarthritis

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

Neuropharmacological Basis of Social Connection: The Role of Opioids

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

Treatment for Opioid Dependent Offenders

Naltrexone in Treatment of Cocaine Dependence - 5

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use

Naltrexone Augmentation of Nicotine Patch Therapy - 1

Behavioral Therapy Plus Naltrexone for Alcoholism

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose

The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion

SSRI and Buprenorphine

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

Focused Ultrasound for the Complex Patient

Narcotics vs NSAIDs for Post-operative Analgesia in Outpatient Rhinoplasty

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

Effects of Dynorphin 1-13 on Heroin Addiction - 1

Attenuation of Pain in Men and Women

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia